Access to Information Requests Completed - June 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the Month of June 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2011-01012 All records related to Colgate Toothbrush Recall. (Apr 1, 2011 to Nov 4, 2011). Disclosed in part 478
A-2012-00827 Summaries, assessments and analyses of media coverage of Nutrition North Canada. (May 1, 2010 to Aug 10, 2012). Disclosed in part 549
A-2012-01027 Documents relating to the article entitled "Noise Annoyance in Canada" (Noise Health. 2005 Apr-Jun;7(27):39-47). Disclosed in part 121
A-2012-01616 Adverse Reaction Report (AER) for Zyprexa. Report numbers: 000376048, 000377471, 000379019, 000383492, 000384744, 000384935, 000388776, 000392050, 000396093, 000411415. Disclosed in part 34
A-2013-00573 Information regarding the medical device LUTONIX 014 DRUG COATED PTA DILATATION CATHETER, License number 91277. Disclosed in part 42
A-2013-00797 Documents regarding whether or not any compassion club in Canada has been authorized by the Minister of Health for any purpose connected to marihuana (such as through an exemption under section56 of the Controlled Drugs and Substances Act). (Jan 1, 1950 to Oct 8, 2013). Disclosed in part 171
A-2013-00965 Adverse Reaction Report (AER) for Buckley's. Report numbers: 000184729, 000216498, 000221169, 000221175, 000221310, 000226624, 000305080, 000314604, 000319304, 000327226, 000331758, 000335989, 000338272, 000339230. Disclosed in part 63
A-2013-00972 Periodic safety update reports filed by McNeil Consumer Healthcare Canada/Johnson and Johnson for all acetaminophen-based products. (Jan 1, 2008 to Nov 13, 2013). No records exist 0
A-2013-00987 Documents between Health Canada and an applicant for a Class II Medical Device Licence containing supporting arguments made by either side for disputed applications. Disclosed in part 41
A-2013-01071 Information regarding Policosanol 10 Mg, Natural Product Number (NPN) 80003259 by SISU Inc. Disclosed in part 279
A-2013-01096 Information regarding the medical device Laser System, License number 70338 by OMEGA LASER SYSTEMS LIMITED. Disclosed in part 357
A-2013-01137 Copies of Module 1, 2 and 3 of the New Drug Submission for Miconazole Nitrate submission number 09059. All exempted 0
A-2013-01234 Clinical trials used to approve Yasmin 21 and Yasmin 28, Drug Identification Number (DIN) 02261723 and 02261731. No records exist 0
A-2013-01327 Information regarding Lymphazurin 1% (Isosulfan Blue), Drug Identification Number (DIN) 00592358. Disclosed in part 142
A-2013-01398 Documents regarding the role of physicians in the new medical marihuana regime taking effect April 1, 2014. (Jan. 1, 2011 to Feb 26, 2014). Disclosed in part 181
A-2013-01430 Reports and/or advice to Natural Resources Canada regarding the Talbot Windfarm / Spence Windfarm, Ontario. (Jan 1, 2003 to Mar 10, 2014). Disclosed in part 37
A-2013-01436 Draft Memorandum of Understanding between Health Canada (HC) and the National Research Council on HC's Collection and amalgamating library services Disclosed in part 5
A-2013-01442 Letter issued prior to March 15, 2006 from Therapeutic Products Directorate to Laboratoire Riva Inc. certifying that the examination of Riva Azithromycin (Azithromycin Monohydrate) 250 mg tablets was complete. Disclosed in part 1
A-2013-01443 Letter issued prior to November 1, 2005 from Therapeutic Products Directorate to Cobalt Pharmaceuticals Inc. certifying that the examination of Co Azithromycin (Azithromycin Monohydrate) 250 mg tablets was complete. Disclosed in part 1
A-2013-01445 Letter issued prior to November 4, 2005 from Therapeutic Products Directorate to Novopharm Limited certifying that the examination of Novo-Azithromycin (Azithromycin Monohydrate Hemiethanolate) 250 mg tablets was complete. Disclosed in part 2
A-2013-01448 Letter issued prior to May 1, 2009 from Therapeutic Products Directorate to Genpharm Inc. certifying that the examination of Gen-Azithromycin (Azithromycin Monohydrate Hemiethanolate) 250 mg tablets was complete. Disclosed in part 1
A-2013-01470 Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Mint Pharmaceuticals Inc. certifying that the examination of MINT-Sildenafil (Sildenafil Citrate) 25, 50 and 100 mg tablets was complete. Disclosed in part 2
A-2013-01471 Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Apotex Incorporated certifying that the examination of APO-Sildenafil (Sildenafil Citrate) 25, 50 and 100 mg tablets was complete. Disclosed in part 2
A-2013-01472 Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Cobalt Pharmaceuticals Company certifying that the examination of Co Sildenafil (Sildenafil Citrate) 25, 50 and 100 mg tablets was complete. Disclosed in part 2
A-2013-01475 Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Mylan Pharmaceuticals ULC certifying that the examination of Mylan-Sildenafil (Sildenafil Citrate) 25, 50 and 100 mg tablets was complete. Disclosed in part 2
A-2013-01476 Letter issued prior to December 18, 2012 from Therapeutic Products Directorate to Teva Canada Limited certifying that the examination of Ratio-Sildenafil was complete. Disclosed in part 1
A-2013-01486 Adverse Reaction Report (AER) for Fludara. Report numbers: E2B_00013112, 000516319. Disclosed in part 137
A-2013-01508 Reports and/or advice to Natural Resources Canada regarding the Talbot Wind Project located in Chatham-Kent, Ontario. (Jan 1, 2003 to Mar 18, 2014). Disclosed in part 37
A-2013-01524 Documents in regards to K2, K2wind, K2 wind Ontario,K2 wind Ltd or any of its parent companies relating to their K2 (Kingsbridge 2) wind farm development. (Jan 1, 2003 to Mar 31, 2014). Disclosed in part 53
A-2013-01530 Adverse Reaction Reports (AER) for Cyklokapron (tranexamic acid) 500 mg. Disclosed in part 10
A-2013-01546 Documents related to consultations conducted between Health Canada officials and public health stakeholders specific to electronic cigarettes. (Sep 1, 2013 to Mar 15, 2014). Disclosed in part 58
A-2013-01549 Exit Notice Report relating to the inspection of Laboratory Matrix located in St-Laurent, Québec. Disclosed in part 9
A-2014-00010 Letter issued prior to March 07, 2014 from Therapeutic Products Directorate to Mint Pharmaceuticals Inc. certifying that the examination of Mint-Latanoprost (Latanoprost) was complete. Disclosed in part 2
A-2014-00017 Letter issued prior to August 25, 2011 from Therapeutic Products Directorate to Cobalt Pharmaceuticals Company certifying that the examination of Co Latanoprost (Latanoprost) was complete. Disclosed in part 2
A-2014-00019 Letter issued prior to December, 6, 2011 from Therapeutic Products Directorate to Sandoz Canada Incorporated certifying that the examination of Sandoz Latanoprost (Latanoprost) was complete. Disclosed in part 2
A-2014-00051 Adverse Reaction Report (AER). Report numbers: 000550077, 000544295, 000544786, 000544308, 000544256. Disclosed in part 25
A-2014-00108 Adverse Reaction Report (AER) for TECTA. Report numbers: 000489695, 000491487, 000499703, 000500722, 000501495, 000503220, 000507946, 000508653, 000509303, 000509435, 000513472, 000513091. Disclosed in part 23
A-2014-00110 Adverse Reaction Report (AER) for Humalog. Report numbers: 000561004, 000576604. Disclosed in part 3
A-2014-00129 Adverse Reaction Report (AER). Report numbers: 000516632, 000524436, 000524561, 000532962, 000533928, 000534316, 000537601, 000537638, 000538820, 000540169, 000540865. Disclosed in part 18
A-2014-00133 Adverse Reaction Report (AER) for ONDANSETRON. Report numbers: 000557076, 000502601, E2B_00021481. Disclosed in part 10
A-2014-00159 Information regarding Sovaldi (Sofosbuvir), Drug Identification Number (DIN) 02418355 by Gilead Sciences Canada Inc. All disclosed 1
A-2014-00160 Adverse Reaction Report (AER) for Calcium Folinate. Report numbers: 000543144, 000541619. Disclosed in part 16
A-2014-00166 Documents regarding the Medical Marihuana Access Program application pertaining to facility Standard Operating Procedures and Threat Risk Assessment or Vulernabilty Evaluation completed on Phytotron's proposed site located in Osoyoos, British Columbia No records exist 0
A-2014-00178 All registries and/or lists of marihuana grow operations in Canada operating. (Jan.1, 2010 to May 15, 2014). No records exist 0
A-2014-00180 All contracts awarded through the ProServices procurement system for services provided within the National Capital Region. (Jan 1, 2013 to Feb 28, 2014). All disclosed 2
A-2014-00181 All contracts awarded via the Temporary Help System (THS) and Task Based Informatics Professional Services (TBIPS), to the companies Excel HR and (Altis HR or Altis Professional) for services provided within the National Capital Region.(Jan 1, 2013 to Feb 28, 2014) Disclosed in part 314
A-2014-00189 Documents to verify whether executives or public servants have asked telecommunication companies or firms for personal data on their Canadian subscribers abroad. (Jan. 1, 2011 to Dec. 31, 2013). No records exist 0
A-2014-00192 Adverse Reaction Report (AER) for Taxotere. Report number: 000563878. Disclosed in part 2
A-2014-00195 Adverse Reaction Report (AER) for Taxotere. Report number: E2B_00033829. Disclosed in part 141
A-2014-00198 Adverse Reaction Report (AER) for Lovenox. Report number: 000573200. Disclosed in part 4
A-2014-00199 Adverse Reaction Report (AER) for Lovenox. Report number: 000573078. Disclosed in part 4
A-2014-00208 Documents pertaining to the number of licences granted for medical marihuana grow operations. (Jun 14, 2001 to Mar 20, 2014). Disclosed in part 45
A-2014-00210 Documents pertaining to the number of licences granted for medical marihuana grow operations. (Mar 21, 2014 to May 6, 2014). All disclosed 1
A-2014-00213 Adverse Reaction Report (AER). Report numbers: 000572262, 000572564, 000574048, 000559518, 000560643. Disclosed in part 10
A-2014-00218 Copy of all statistics or other data detailing the number of phone calls received by the police force to verify certain information, does a suspicious individual really hold a valid medical marihuana grow operation license. (Jan 1, 2001 to May 13, 2014). All disclosed 1
A-2014-00219 Adverse Reaction Report (AER). Report number: 000563175. Disclosed in part 1
A-2014-00235 Adverse Reaction Report (AER). Report numbers: 000575425, 000558500, 000565203. Disclosed in part 5
A-2014-00241 Adverse Reaction Report (AER) for Androgel. Report number: 000571878. Disclosed in part 1
A-2014-00242 Adverse Reaction Report (AER) for Luvox. Report numbers: 000558815, 000564876. Disclosed in part 3
A-2014-00243 Adverse Reaction Report (AER) for Mavik. Report number: 000569102. Disclosed in part 1
A-2014-00244 Adverse Reaction Report (AER) for Biaxin. Report number: 000568333. Disclosed in part 2
A-2014-00250 Adverse Reaction Report (AER). Report number: 000578755. Disclosed in part 5
A-2014-00252 Copies of all investigative reports and other data which have led to sanctions for inappropriate use of computer equipment. (Jan. 1, 2011 to May 16, 2014). Disclosed in part 147
A-2014-00256 All briefing notes for the Minister regarding neonicotinoids. (Jan 1, 2013 to May 22, 2014). All disclosed 12
A-2014-00259 Adverse Reaction Report (AER) for MICARDIS. Report number: 000476872. Disclosed in part 1
A-2014-00262 Adverse Reaction Report (AER) for Eloxatin. Report number: E2B_00031944. All disclosed 12
A-2014-00263 Adverse Reaction Report (AER) for Eloxatin. Report number: 000562244. Disclosed in part 2
A-2014-00264 Adverse Reaction Report (AER) for Eloxatin. Report number: 000562554. Disclosed in part 1
A-2014-00266 Adverse Reaction Report (AER) for Eloxatin. Report number: 000559391. Disclosed in part 2
A-2014-00269 Adverse Reaction Report (AER) for Aerius. Report numbers: 000502569, 000457900, 000457899, 000455116, 000437349, 000396782, 000381586, 000509337. Disclosed in part 11
A-2014-00271 Adverse Reaction Report (AER) for Gliclazide. Report numbers: 000338972, 000470372. Disclosed in part 2
A-2014-00278 Adverse Reaction Report (AER) for Andriol. Report number: 000453816. Disclosed in part 2
A-2014-00279 Adverse Reaction Report (AER) for Claritin. Report numbers: 000484380, 000435891, 000436346, 000445329. Disclosed in part 4
A-2014-00280 Adverse Reaction Report (AER) for Coricidin. Report numbers: 000380855, 000384262. Disclosed in part 2
A-2014-00281 Adverse Reaction Report (AER) for Cosopt. Report numbers: 000400679, 000432632. Disclosed in part 2
A-2014-00282 Adverse Reaction Report (AER) for Cotazym. Report number: 000380802. Disclosed in part 1
A-2014-00283 Adverse Reaction Report (AER) for Cozaar. Report numbers: 000468873, 000452200, 000435226, 000406321. Disclosed in part 5
A-2014-00284 Adverse Reaction Report (AER) for Elocom. Report number: 000441953. Disclosed in part 3
A-2014-00287 Briefing notes to the Minister about the increase of bariatric surgeries, including associated risks and costs. (Jan 1 2014 to May 30, 2014). No records exist 0
A-2014-00289 Briefing notes to the Minister, risk analysis and communications plans/strategies, around the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). (Mar 1, 2014 to May 30, 2014). Disclosed in part 10
A-2014-00312 Adverse Reaction Report (AER) for Emend. Report number: 000465569. Disclosed in part 2
A-2014-00313 Adverse Reaction Report (AER) for Estrogel. Report numbers: 000409456, 000428520, 000473903, 000476911, 000491375. Disclosed in part 7
A-2014-00316 Adverse Reaction Report (AER) for Ezetrol. Report numbers: 000474638, 000474017, 000472824, 000469358, 000461853, 000410977, 000407867, 000484378. Disclosed in part 11
A-2014-00317 Adverse Reaction Report (AER) for Fosamax. Report numbers: 000483569, 000474596, 000456212, 000439509, 000510846, 000505486, 000401852, 000492827, 000488487, 000484217, 000482362, 000479096, 000477658, 000477645, 000470208, 000469849, 000462803, 000451204, 000450146, 000442362, 000435253, 000426118, 000410189, 000403800. Disclosed in part 41
A-2014-00318 Adverse Reaction Report (AER) for Fosavance. Report numbers: 000505489, 000468253, 000434992, 000432276, 000429485, 000429188, 000424380, 000419203, 000415204, 000422297, 000439948, 000442292, 000463888, 000474655, 000493347. Disclosed in part 27
A-2014-00319 Adverse Reaction Report (AER) for Garamycin. Report numbers: 000446217, 000435862. Disclosed in part 2
A-2014-00320 Adverse Reaction Report (AER) for Garasone. Report number: 000413953. Disclosed in part 2
A-2014-00321 Adverse Reaction Report (AER) for Gardasil. Report numbers: 000509301, 000411615, 000438175, 000445637, 000457935, 000496867, 000504294, 000504081, 000484024, 000460512, 000457789, 000449128, 000448900, 000439568, 000433158, 000410120. Disclosed in part 57
A-2014-00322 Adverse Reaction Report (AER) for Hyzaar/DS. Report numbers: 000408940, 000467469, 000455952. Disclosed in part 4
A-2014-00324 Adverse Reaction Report (AER) for Invanz. Report numbers: 000441377, 000453183, 000484860, 000498991. Disclosed in part 6
A-2014-00325 Adverse Reaction Report (AER) for Janumet. Report numbers: 000502785, 000500415, 000467393, 000505375, 000503615, 000489162, 000485701, 000459996, 000455861. Disclosed in part 11
A-2014-00351 Documents relating to: Authorizing the transfer of marihuana or cannabis from a Marihuana Medical Access Regulations (MMAR) licensee to a Marihuana for Medical Purposes Regulations (MMPR) licensee on or after April 1, 2014. No records exist 0
Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: